LIABILITIES AND EQUITY Sample Clauses

LIABILITIES AND EQUITY. Liabilities Current Liabilities: Accounts Payable – Due to Elan 113,260 129,229 Accounts Payable – Due to Acorda — 721,000 Total Accounts Payable 113,260 850,229 Total current liabilities 113,260 850,229 Total liabilities 113,260 850,229 Equity Contributed Surplus Contributed Surplus Acorda 8,213,265 8,213,265 Contributed Surplus EIS 1,279,409 1,279,409 9,492,674 9,492,674 Retained Earnings (24,605,943 ) (25,342,912 ) Share Capital Common Shares Acorda 20 21 Common Shares EPIL II 3 3 Common Shares EIS 1 — 24 24 Share Premium Acorda 12,014,988 12,014,988 EIS 2,984,997 2,984,997 14,999,985 14,999,985 Total liabilities and stockholders’ equity — — SCHEDULE 4.4.2 MS R&D THIRD PARTY AGREEMENTS Agreements to which MS R&D is a party None Agreements to which Elan is a party for the benefit of MS R&D 1 Confidentiality Agreement dated February 24, 2000 between Elan Corporation plc and Regis Technologies, Inc 2 Confidentiality Agreement dated May 1, 2002 between Elan Corporation plc and Magellan Laboratories, Inc 3 Confidentiality Agreement dated April 12, 2000 between Elan Corporation plc and Regulatory Interlinx 4 Confidentiality Agreement dated December 8, 1997 between Elan Corporation plc and CU Chemie Uetikon GmbH 5 Supply Agreement dated December 8, 2000 between Elan Pharma Limited and Regis Technologies Inc 6 Letter Agreement dated June 26, 2000 between Elan Pharmaceutical Operations and CU Chemie Uetikon GmbH Agreements to which Elan and Acorda are parties for the benefit of MS R&D Confidentiality Agreement dated December 5, 2002 between Elan Corporation plc, Patheon Inc. and Acorda Therapeutics, Inc Agreements to which Elan and Acorda are parties for the benefit of MS R&D 2 Jeiven/Almedica dated November 14, 2002 3 Pharmanet dated October 25, 2001 4 Cardinal Health dated April 1, 2003 5 ClinPro, Inc. dated July 30, 2002 6 Patheon, Inc. dated February 26, 2003 Clinical Study Agreements*
Sample 1Sample 2
AutoNDA by SimpleDocs
LIABILITIES AND EQUITY. Current Liabilities
Sample 1
LIABILITIES AND EQUITY. Liabilities Current Liabilities: Accounts Payable — Due to Elan 113,260 129,229 Accounts Payable — Due to Acorda — 565,511 Accounts Payable — Other 26,260 Total Accounts Payable 113,260 721,000 Total current liabilities 113,260 721,000 Total liabilities 113,260 721,000 Equity Contributed Surplus Contributed Surplus Acorda 8,213,265 8,213,265 Contributed Surplus EIS 1,279,409 1,279,409 9,492,674 9,492,674 Retained Earnings (24,605,943 ) (25,213,683 ) Share Capital Common Shares Acorda 20 21 Common Shares EPIL II 3 3 Common Shares EIS 1 — 24 24 Share Premium Acorda 12,014,988 12,014,988 EIS 2,984,997 2,984,997 14,999,985 14,999,985
Sample 1
LIABILITIES AND EQUITY. The 2019 balance sheet liabilities and equity, noted on Schedule F-1 of the annual report, totaled $(5,121,822). Audit verified the total liabilities and equity to the general ledger, as well as to Schedule 4 (pdf page 27 of 107 of the “20-187_2021-01-15_ lwrc_perm_rate_schedules.pdf”) of the filing: Equity Capital $ (2,971,220) Long-term Debt (915,541) Current and Accrued Liabilities (96,879) Deferred Credits (578,931) Contributions in Aid of Construction (559,251) Total Equity Capital and Liabilities $ (5,121,822) Equity Capital $(2,971,220) Audit verified that the total equity capital consisted of the following general ledger account balances: Common Stock Issued $ (10,000) Other Paid-in Capital (1,423,322) Capital Stock Expense (4) Retained Earnings (1,537,894) Total Equity Capital Common Stock $(10,000) $ (2,971,220) Schedule 4 of the filing reports the Common Stock total of $(10,000), as of December 31, 2019. This total agrees with the PUC annual report, as well as with the general ledger account 201, Common Stock. The Company’s sole shareholder is the director, Xxxxxxx X. Xxxxx. There was no activity reported on the account during the 2019 test year. Audit noted that the Common Stock total of $(10,000) has remained constant since the prior rate case in 2014. Other Paid-in Capital $(1,423,322)
Sample 1

Related to LIABILITIES AND EQUITY

  • ERISA Liabilities The Borrower shall not, and shall cause each of its ERISA Affiliates not to, (i) permit the assets of any of their respective Plans to be less than the amount necessary to provide all accrued benefits under such Plans, or (ii) enter into any Multiemployer Plan.

  • Liabilities and Indemnities The Sponsor shall indemnify the Participating Site and its Agents, against any reasonable claims, proceedings and related costs, expenses, losses, damages and demands to the extent they arise or result from the negligent acts or omissions of, or the wilful misconduct of the Sponsor, and/or contracted third party, in its performance of this Agreement or in connection with the Non-Interventional Study. The CRO shall indemnify the Participating Site and its Agents, against any reasonable claims, proceedings and related costs, expenses, losses, damages and demands to the extent they arise or result from the negligent acts or omissions of, or the wilful misconduct of the CRO, and/or contracted third party, in its performance of this Agreement or in connection with the Non-Interventional Study. The Sponsor and the CRO shall maintain all proper insurance arrangements to cover liabilities arising from their conduct in the Non-Interventional Study, in respect of any claims brought by or on behalf of a Non-Interventional Study Subject. The Sponsor and the CRO shall provide the Participating Site such evidence of their insurance maintained pursuant to clauses 5.1 and 5.2 as the Participating Site shall from time to time reasonably request. In no circumstances shall any Party be liable to another Party in contract, tort or delict (if the Participating Organisation is constituted in Scotland) (including negligence or breach of statutory duty) or otherwise howsoever arising or whatever the cause thereof, for any loss of profit, business, reputation, contracts, revenues or anticipated savings or for any special, indirect or consequential damage of any nature, which arises directly or indirectly from any default on the part of any other Party. Subject to Clauses 5.6 and 5.7 the Participating Organisation’s liability to the Sponsor and CRO arising out of or in connection with any breach of this Agreement or any act or omission of the Participating Organisation in connection with the performance of the Non-Interventional Study shall in no event exceed the amount of fees payable by the Sponsor or CRO to the Participating Organisation under this Agreement. [DELETE IF NOT APPLICABLE] In the case of equipment loaned to the Participating Organisation for the purposes of the Non-Interventional Study, the Participating Organisation’s liability for loss or damage to this equipment arising from its negligence shall exclude fair wear and tear and shall not exceed the value of the equipment. In respect of any wilful and/or deliberate breach by the Participating Organisation, or any breach of Clauses 6, 8, 10 or 11 the Participating Organisation’s liability to the Sponsor and CRO arising out of or in connection with the breach shall not exceed two times the value of the Agreement. Nothing in this Clause 5 shall operate so as to restrict or exclude the liability of any Party in relation to death or personal injury caused by the negligence or wilful misconduct of that Party or its Agents or employees, or to restrict or exclude any other liability of any Party that cannot be so restricted or excluded in law. Nothing in this Agreement will operate to limit or exclude any liability for fraud.

  • Liabilities and Warranties While the Custodian will take reasonable precautions to ensure that information provided is accurate, the Custodian shall have no liability with respect to information provided to it by third parties. Due to the nature and source of information, and the necessity of relying on various information sources, most of which are external to the Custodian, the Custodian shall have no liability for direct or indirect use of such information.

  • Liabilities If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any party to any other party except as provided in Section 4 hereof, and provided further that Sections 1, 6, 7 and 8 shall survive such termination and remain in full force and effect.

  • LIABILITIES AND INDEMNIFICATION SMC shall be liable for any actual losses, claims, damages or expenses (including any reasonable counsel fees and expenses) resulting from SMC's bad faith, willful misfeasance, reckless disregard of its obligations and duties, negligence or failure to properly perform any of its responsibilities or duties under this agreement. SMC shall not be liable and shall be indemnified and held harmless by the Fund, for any claim, demand or action brought against it arising out of, or in connection with:

  • Material Liabilities The Company has no material liability or obligation, absolute or contingent (individually or in the aggregate), except (i) obligations and liabilities incurred after the date of incorporation in the ordinary course of business that are not material, individually or in the aggregate, (ii) obligations under the Notes and in connection with the Advance and (iii) as contemplated by the Merger Agreement and the Transaction Documents.

  • ADVISER’S LIABILITIES AND INDEMNIFICATION (a) The Adviser shall have responsibility for the accuracy and completeness (and liability for the lack thereof) of the statements in each Fund’s offering materials (including the prospectus, the statement of additional information, advertising and sales materials), relating to (i) the Adviser and its affiliates, (ii) the Fund’s investment strategies and related risks, and (iii) other information, in each case only if supplied by the Adviser for inclusion therein.

  • Liabilities of the Adviser A. In the absence of willful misfeasance, bad faith, gross negligence, or reckless disregard of obligations or duties hereunder on the part of the Adviser, the Adviser shall not be subject to liability to the Trust or the Fund or to any shareholder of the Fund for any act or omission in the course of, or connected with, rendering services hereunder or for any losses that may be sustained in the purchase, holding or sale of any security by the Fund.

  • LIABILITIES OF THE PARTIES 4.1 For non-performance or improper performance of the obligations under this Agreement, the parties shall be liable in accordance with the current legislation of the Russian Federation.

  • Securities Act Liabilities Any provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the terms of this Agreement to indemnify Indemnitee or otherwise act in violation of any undertaking appearing in and required by the rules and regulations promulgated under the Securities Act of 1933, as amended (the “Act”), or in any registration statement filed with the SEC under the Act. Indemnitee acknowledges that paragraph (h) of Item 512 of Regulation S-K currently generally requires the Company to undertake in connection with any registration statement filed under the Act to submit the issue of the enforceability of Indemnitee’s rights under this Agreement in connection with any liability under the Act on public policy grounds to a court of appropriate jurisdiction and to be governed by any final adjudication of such issue. Indemnitee specifically agrees that any such undertaking shall supersede the provisions of this Agreement and to be bound by any such undertaking.

Time is Money Join Law Insider Premium to draft better contracts faster.